Loading...
•
Sep 30, 2024
Vanda Q3 2024 Earnings Report
Vanda reported a net loss of $5.3 million and total revenues of $47.7 million, a 23% increase compared to Q3 2023.
Key Takeaways
Vanda Pharmaceuticals reported Q3 2024 financial results, with revenues of $47.7 million, a 23% increase compared to Q3 2023. The company launched Fanapt® in bipolar I disorder and PONVORY® for multiple sclerosis. A net loss of $5.3 million was reported, and financial guidance for the full year 2024 was revised, raising the midpoint of revenue and cash ranges.
Total revenues for Q3 2024 were $47.7 million, a 23% increase compared to Q3 2023.
Fanapt® launch in bipolar I disorder led to a new patient start increase of over 90% compared to Q3 2023.
PONVORY® commercial launch for multiple sclerosis was initiated in Q3 2024.
Financial Guidance revised for Full Year 2024, raising the midpoint of revenue and cash ranges.
Forward Guidance
Vanda is updating its 2024 financial guidance and expects to achieve total revenues between $190 to $210 million and year-end cash between $370 to $390 million.
Positive Outlook
- Total revenues are expected to be between $190 to $210 million.
- Year-end cash is expected to be between $370 to $390 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...